Disopyramide Phosphate Tablets

This product belongs to the class I alpha; antiarrhythmic drugs. Its electrophysiology and hemodynamics are similar to quinidine. It has the effect of inhibiting the influx of fast sodium ions, prolonging the action potential and effective refractory period, reducing the conduction velocity of the atrium and the accessory bundle, reducing the autonomy of the myocardial conduction fibers, inhibiting the excitability of the atrium and ventricular muscles, and reducing the myocardial contractility. In addition, it has a more obvious anticholinergic effect, so it may accelerate the frequency of the sinus node and the conduction velocity of the atrioventricular junction, but the condition of patients with existing sick sinus syndrome or atrioventricular conduction disorders may still be aggravated. Animal studies have not confirmed teratogenicity.

The main ingredients of this product are: disopyramide phosphate. Molecular formula: C21H29N3OH3PO4 Molecular weight: 437.47

This product is white tablets.

For life-threatening ventricular arrhythmias that are ineffective with other drugs.

Common oral dosage for adults: 0.2g for the first dose, 0.1-0.15g thereafter, once every 6 hours. The dosage should be adjusted according to needs and tolerance.

1. Cardiovascular ① Overdose can cause apnea, loss of consciousness, cardiac arrest, conduction block and ventricular arrhythmia, and the electrocardiogram shows PR interval prolongation, QRS wave widening and Q-T prolongation, torsades de pointes and ventricular fibrillation; ② Negative inotropic effect is the most important adverse reaction of this product, which can cause 50% of patients to relapse or worsen heart failure. The chance of heart failure in patients without a history of heart failure is less than 5%, which can cause hypotension and even shock; ③ It has been reported that intravenous injection can produce significant coronary artery contraction. 2. Anticholinergic effect is the most common adverse reaction of this product, including dry mouth, urine retention, frequent urination, urgent urination, constipation, blurred vision, aggravated glaucoma, etc. 3. Gastrointestinal nausea, vomiting, anorexia, diarrhea. 4. Liver Hepatic cholestasis or abnormal liver function. 5. Blood granulocytopenia.

The following conditions should not be used: 1. II or III degree atrioventricular block and bifascicular block (unless a pacemaker is already in place). 2. Sick sinus syndrome. 3. Cardiogenic shock. 4. Glaucoma. 5. Urinary retention, most commonly caused by prostatic hypertrophy. 6. Myasthenia gravis.

1 When used in combination with other antiarrhythmic drugs, it can further prolong the conduction time and inhibit cardiac function. 2 When used in combination with moderate to large amounts of ethanol, the chances of hypoglycemia and hypotension increase due to synergistic effects. 3 When used in combination with warfarin, the anticoagulant effect can be more obvious. 4 When used in combination with drug enzyme inducers such as phenobarbital, phenytoin sodium and rifampicin, it can induce the metabolism of this product. In some patients, this product can induce its own metabolism.

Keep away from light and store in sealed container.

0.1 g

Southwest Pharmaceutical Co., Ltd.

• Founded in:

  2015-01-08

• Address:

  No. 21 Tianxing Bridge, Shapingba District, Chongqing

• Tax NO.:

  915000003316906249

• Registered Funds:

  490.146298 million yuan

• Website:

  Log in to view

• Email:

  Log in to view